Wells Fargo’s Lipella Pharmaceuticals LIPO Stock Holding History

Wells Fargo’s Portfolio LIPO Stock Details LIPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4	Closed	-$21	–	7218
2024 Q1	$21	Hold	4	–	–	﹤0.01%	7098
2023 Q4	$30	Hold	4	–	–	﹤0.01%	7070
2023 Q3	$42	Buy	4 +3	+300%	+$49	﹤0.01%	6964
2023 Q2	$19	Hold	1	–	–	﹤0.01%	7312
2023 Q1	$16	Buy	+1	New	+$20	﹤0.01%	7423

Other funds holding LIPO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's LIPO Position: Q2 2024 in Review

Wells Fargo sold out of Lipella Pharmaceuticals (LIPO) in Q2 2024, closing a stake of 4 shares — an estimated $21 sold.

Wells Fargo first reported a position in LIPO in Q1 2023 and held it in 5 quarters. The position peaked at $42 in Q3 2023. 7 funds tracked by Wall St. Rank hold LIPO as of Q2 2024.

Wells Fargo reported no remaining Lipella Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 4 Lipella Pharmaceuticals shares in Q2 2024, an estimated $21.
Wells Fargo first reported a position in Lipella Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Wells Fargo's Lipella Pharmaceuticals position peaked at $42 in Q3 2023.
7 funds tracked by Wall St. Rank held Lipella Pharmaceuticals as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.